US Patent

US10646484 — Methods to treat opioid use disorder

Method of Use · Assigned to Indivior UK Ltd · Expires 2038-06-22 · 12y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods for using sustained-release buprenorphine formulations to treat opioid use disorder.

USPTO Abstract

The disclosure provides sustained-release buprenorphine formulations that produce therapeutic plasma concentration levels of buprenorphine in patients to treat opioid use disorder.

Drugs covered by this patent

Subutex (BUPRENORPHINE) · Purdue Pharma Lp

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2489`	—	Subutex

Patent Metadata

Patent number: US10646484
Jurisdiction: US
Classification: Method of Use
Expires: 2038-06-22
Drug substance claim: No
Drug product claim: No
Assignee: Indivior UK Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.